Microvascular Angina in Women: Chest Pain When the Big Arteries Are Fine

Coronary microvascular dysfunction affects the smallest coronary vessels, those under 500 micrometers, which account for over 90% of coronary vascular resistance but remain invisible on standard angiography. The WISE study documented this condition in more than 50% of women catheterized for chest pain with non-obstructive arteries, finding a 27.6% major adverse cardiovascular event rate over five years when coronary flow reserve fell below 2.32. Diagnosis requires specialized testing: invasive coronary function assessment, stress cardiac MRI, or PET perfusion imaging. Treatment with ranolazine, beta-blockers, and ACE inhibitors can reduce angina episodes by half. This is not anxiety. This is cardiac disease.

The Diagnosis That Was Invisible

She had chest pain with exertion for three years. Two catheterizations showed clean arteries. Three cardiologists told her it was anxiety. The WISE study from 2006 has a name for this: coronary microvascular dysfunction. She had a real diagnosis.

I met her on a Tuesday afternoon. She was 54. She brought a folder containing three years of records, two normal stress tests, two catheterization reports documenting “no significant coronary artery disease,” and one prescription for sertraline from a physician who suggested her symptoms were psychosomatic. Her chest pain was typical. It came with exertion, radiated to her left arm, and resolved with rest. Every criterion for angina pectoris.

The problem was simple. Her coronary arteries were normal. The catheterization images showed pristine vessels, wide open, no plaques, no blockages. In the traditional model of coronary disease, she had nothing wrong.

The traditional model was wrong.

Coronary microvascular dysfunction is a functional and structural abnormality of the coronary microcirculation. These are the arterioles smaller than 500 micrometers and the capillaries that feed the heart muscle directly. They account for more than 90% of coronary vascular resistance. They are invisible on standard angiography. They can be severely impaired while the big arteries look perfect. Camici et al. 2015 established the mechanistic framework: impaired endothelium-dependent vasodilation, abnormal smooth muscle relaxation, structural remodeling of the microvessels, and inadequate coronary flow reserve. 5 / Solid

The patient in my office that Tuesday did not have anxiety. She had a disease of her coronary circulation that three catheterizations could not see because nobody looked at the right vessels.

What the WISE Study Proved

The Women’s Ischemia Syndrome Evaluation, or WISE, was an NHLBI-sponsored study that began in 1996 and changed cardiology. The researchers enrolled 936 women referred for coronary angiography because of suspected ischemia. What they found rewrote the textbooks.

Among women catheterized for chest pain, over 50% had non-obstructive coronary artery disease. In conventional thinking, these women had no explanation for their symptoms. They were discharged with reassurance. Many were told the problem was psychological.

The WISE investigators did not accept this. They measured coronary flow reserve, the ratio of maximal to resting coronary blood flow. In women with non-obstructive arteries and impaired flow reserve, the 5-year major adverse cardiovascular event rate was 27.6%. In those with preserved flow reserve, it was 10.5%. Bairey Merz et al. 2006 proved that clean arteries did not mean clean bills of health. 5 / Solid

This was not a marginal finding. The adverse event rate in women with CMD and normal-appearing arteries was higher than many physicians would expect in patients with moderate obstructive disease. Heart attacks. Strokes. Heart failure hospitalizations. Deaths. All in women who had been told nothing was wrong.

The WISE study gave this entity a name and a prognosis. Before 2006, coronary microvascular dysfunction was a hypothesis. After 2006, it was a diagnosis. The problem was that it took another decade for most cardiology practices to catch up.

Women don’t die from what they have. Women die from what they hold.

The Anatomy Nobody Taught Us

Understanding why this happens requires understanding coronary anatomy beyond what most medical education provides.

The coronary arteries that show up on angiography are the epicardial vessels. They sit on the surface of the heart. They are 2 to 4 millimeters in diameter. They are what cardiologists learned to fix with stents and bypass grafts. They are not the whole story.

Below these surface vessels lies the coronary microcirculation. Arterioles between 100 and 500 micrometers. Pre-arterioles. Capillaries. These vessels penetrate into the heart muscle itself. They regulate blood flow at the tissue level. They respond to metabolic demand. They control vascular resistance. They are responsible for matching oxygen supply to oxygen demand beat by beat.

The microcirculation cannot be seen on standard angiography. A coronary catheterization that shows “no significant disease” shows only that the epicardial arteries are open. It says nothing about whether blood can actually reach the heart muscle in adequate quantities. It is like examining only the main highways and declaring the transportation system functional while every local road is impassable.

In CMD, the microvessels fail. The mechanisms are multiple. Endothelial cells lose their ability to release nitric oxide. Smooth muscle cells contract when they should relax. The vessels remodel structurally, with thickened walls and narrowed lumens. The result is the same: the heart cannot get enough blood during demand, even though the big arteries are wide open.

Taqueti et al. 2017 demonstrated that women referred for angiography had excess cardiovascular risk relative to men, and this excess risk was driven by severely impaired coronary flow reserve, not by obstructive epicardial disease. The study quantified what WISE had established: the microvessels matter, and they matter more in women. 5 / Solid

How We Diagnose What We Cannot See

If standard angiography cannot visualize the microcirculation, how do we diagnose microvascular dysfunction? The answer is functional testing. We measure what the microvessels do rather than trying to see what they look like.

The gold standard is invasive coronary function testing. During a standard catheterization, specialized wires are passed into the coronary arteries. These wires measure pressure and flow. The key metrics are coronary flow reserve and the index of microcirculatory resistance, or IMR.

Coronary flow reserve is the ratio of blood flow during maximal vasodilation to blood flow at rest. A healthy microcirculation can increase flow by at least two and a half times baseline. A CFR below 2.0 is diagnostic of CMD. Some authorities use 2.5 as the threshold. The IMR directly assesses microcirculatory resistance. An IMR above 25 confirms microvascular dysfunction. Ong et al. 2018 published international consensus criteria standardizing these diagnostic thresholds. 5 / Solid

The CorMicA trial took this further. Ford et al. 2018 randomized 151 patients with angina and non-obstructive coronary disease to invasive coronary function testing versus standard care. Those who received the invasive assessment and had treatment guided by the findings had significantly improved angina at 6 months. The study proved that finding the diagnosis changed outcomes. 4 / Promising

Non-invasive options exist for patients who cannot undergo or do not need catheterization. Stress cardiac MRI with perfusion imaging can demonstrate ischemia in a pattern consistent with microvascular disease. PET myocardial perfusion imaging can quantify myocardial blood flow and coronary flow reserve without catheterization. Transthoracic Doppler echocardiography of the left anterior descending artery can estimate CFR in experienced hands.

The diagnostic pathway depends on clinical context. A woman with persistent typical angina after a non-obstructive angiogram should be offered coronary function testing. A woman being evaluated for the first time might start with stress cardiac MRI. The point is that diagnosis is possible. The technology exists. The question is whether anyone orders the test.

Treatment That Actually Works

The diagnosis matters because treatment is possible. The 2020 EAPCI Expert Consensus Document on Ischemia with Non-Obstructive Coronary Arteries established treatment algorithms based on the underlying mechanism. Kunadian et al. 2020 provided the framework that modern practice follows. 5 / Solid

Ranolazine is the medication with the strongest evidence specifically for CMD. It works through a novel mechanism. By inhibiting the late sodium current in cardiac cells, ranolazine reduces intracellular calcium overload and improves diastolic relaxation. It does not affect heart rate or blood pressure significantly. Clinical trials demonstrate a 50% reduction in angina episodes in patients with CMD. Bairey Merz et al. 2020 reviewed the evidence and endorsed ranolazine as first-line therapy for microvascular angina. 4 / Promising

Beta-blockers reduce myocardial oxygen demand by slowing heart rate and reducing contractility. They are particularly useful when chest pain occurs with tachycardia or exertion. For women whose symptoms are triggered by exercise, beta-blockers can restore the ability to be active without pain.

ACE inhibitors and angiotensin receptor blockers address endothelial dysfunction directly. By reducing angiotensin II signaling, these medications improve nitric oxide bioavailability and restore endothelial vasodilatory function. They are foundational therapy for any patient with CMD.

Statins have anti-inflammatory effects on the microcirculation independent of their LDL-lowering action. Even in patients with normal cholesterol, statins reduce microvascular inflammation and improve endothelial function.

Calcium channel blockers are useful when vasospasm is part of the clinical picture. Many women with CMD have an overlap with coronary vasospasm, where the vessels actively constrict. Amlodipine or diltiazem can prevent these episodes.

Lifestyle modification is not optional. Smoking cessation is mandatory. Exercise training, specifically supervised cardiac rehabilitation, improves microvascular function. Weight management reduces the metabolic stress on the cardiovascular system. These interventions work.

The iPOWER study from Denmark enrolled 963 women with angina and no obstructive coronary disease. Jespersen et al. 2016 identified the cardiovascular risk factors that predicted CMD in this population: hypertension, diabetes, smoking, and elevated BMI. Treating these risk factors aggressively is part of treating CMD itself. 5 / Solid

Why This Diagnosis Keeps Getting Missed

The patient I described earlier, the one with three years of symptoms and three dismissive cardiologists, is not unusual. She is typical. The question is why.

The history of cardiology is a history of male-pattern coronary disease. The classic studies of the 1950s and 1960s focused on middle-aged men with crushing chest pain and massive heart attacks from blocked arteries. The diagnostic frameworks were built around men. The clinical trials enrolled men. The treatments were tested in men.

When women presented differently, with diffuse disease rather than focal blockages, with microvascular dysfunction rather than obstructive plaques, the existing framework had no category for them. The diagnosis was not “different type of heart disease.” The diagnosis was “no heart disease found.” From there, anxiety was a short step.

Medical education reinforced this. When I trained, coronary disease meant blockages. A clean angiogram meant a negative workup. Microvascular dysfunction was mentioned, if at all, as a curiosity rather than a diagnosis with a 27.6% event rate.

The technology also contributed. Angiography shows what it shows: the big arteries. The microvessels are invisible. Without specialized testing, the disease cannot be seen. And specialized testing was not part of routine catheterization protocols.

The result was a generation of women diagnosed with anxiety when they had cardiac disease. A generation told to see psychiatrists when they needed cardiologists. A generation who carried real risk while being reassured that nothing was wrong.

This is changing. The WISE study made it possible to name the condition. The EAPCI consensus document made it possible to standardize diagnosis and treatment. The CorMicA trial proved that finding the diagnosis improved outcomes. The science is clear. The challenge now is implementation.

The Clinical Framework: The Microvascular Recognition Protocol

For the women reading this, and for the physicians who care for them, I propose a structured approach: The Microvascular Recognition Protocol.

First, recognize the pattern. The typical presentation is exertional chest pain in a woman with cardiovascular risk factors and a catheterization showing non-obstructive coronary disease. The pain is classic angina. It occurs with effort, radiates, and resolves with rest. The difference is that the angiogram does not show the expected blockages.

Second, request functional testing. After a non-obstructive angiogram, the workup is not complete. Ask for invasive coronary function testing with CFR and IMR measurement. If invasive testing is not available or appropriate, request stress cardiac MRI with perfusion imaging. If neither is accessible, request PET myocardial perfusion with quantitative flow analysis.

Third, treat what you find. A CFR below 2.0 and an IMR above 25 establish the diagnosis. Start ranolazine. Add a beta-blocker if heart rate is elevated. Add an ACE inhibitor for endothelial dysfunction. Add a statin for inflammation. Refer for cardiac rehabilitation. Treat every modifiable risk factor aggressively.

Fourth, follow the outcome. Angina frequency should improve within weeks. Quality of life should improve within months. If symptoms persist, reconsider the diagnosis. Reassess for vasospasm. Consider overlap syndromes. Adjust treatment.

This protocol does not require exotic technology. It requires only the recognition that non-obstructive coronary disease is not the same as no coronary disease. It requires only the willingness to test for what cannot be seen directly. It requires only treating what we find.

What to Do Next

If you have chest pain and a catheterization that showed normal or non-obstructive arteries, you may have coronary microvascular dysfunction. The diagnosis explains your symptoms. The diagnosis carries real risk. The diagnosis is treatable.

At your next cardiology appointment, bring this article. Ask three specific questions. First, can I be tested for coronary microvascular dysfunction? Second, what is my coronary flow reserve? Third, if my flow reserve is impaired, what is the treatment plan?

If your cardiologist does not perform invasive coronary function testing, ask for a referral to a center that does. If invasive testing is not feasible, ask about stress cardiac MRI with perfusion imaging or PET myocardial perfusion scanning. Do not accept “your arteries are fine” as a final answer when you are having classic angina and your quality of life is suffering.

Print the names of these tests: coronary flow reserve, index of microcirculatory resistance, stress cardiac MRI with perfusion, PET myocardial blood flow quantification. These are the tests that diagnose what standard angiography cannot see.

For related information on heart conditions with normal-appearing arteries, read about MINOCA: Heart Attack with Normal Arteries, ANOCA: Angina with Normal Coronary Arteries, and Coronary Vasospasm in Women. For diagnostic approaches, see Cardiac MRI for Women. For understanding the difference between cardiac and non-cardiac symptoms, read Chest Pain: Anxiety vs Cardiac in Women.

Frequently Asked Questions

Can you have heart disease with normal coronary arteries on a heart catheterization?

Yes, and this is more common than most physicians recognize. Standard angiography visualizes only the epicardial coronary arteries, those vessels 2 to 4 millimeters in diameter that sit on the heart’s surface. The coronary microcirculation, comprising arterioles smaller than 500 micrometers and capillaries, is invisible on angiography. These small vessels account for over 90% of coronary vascular resistance. When they fail, the heart becomes ischemic despite pristine large arteries. The WISE study found this pattern in more than half of women catheterized for chest pain with non-obstructive findings. The diagnosis requires functional testing, specifically coronary flow reserve measurement, not anatomic imaging.

What tests can diagnose coronary microvascular dysfunction?

The gold standard is invasive coronary function testing performed during cardiac catheterization. Specialized pressure and flow wires measure coronary flow reserve and the index of microcirculatory resistance. A CFR below 2.0 and IMR above 25 establish the diagnosis. Non-invasive alternatives include stress cardiac MRI with perfusion imaging, which demonstrates ischemia in patterns consistent with microvascular disease, and PET myocardial perfusion imaging, which can quantify myocardial blood flow and calculate CFR without catheterization. Transthoracic Doppler echocardiography of the left anterior descending artery can estimate CFR in experienced laboratories. The choice depends on clinical context, available expertise, and whether catheterization is already planned.

What medications treat microvascular angina in women?

Ranolazine has the strongest specific evidence, reducing angina episodes by approximately 50% in clinical trials through its mechanism of inhibiting the late sodium current in cardiac cells. Beta-blockers reduce myocardial oxygen demand and are particularly effective when symptoms occur with exertion or elevated heart rate. ACE inhibitors address endothelial dysfunction by improving nitric oxide bioavailability. Statins reduce microvascular inflammation independent of their cholesterol effects. Calcium channel blockers are added when vasospasm is part of the clinical picture. Treatment is typically multimodal, combining medications that address different mechanisms. Cardiac rehabilitation improves microvascular function through supervised exercise training.

Is microvascular angina dangerous or just uncomfortable?

Microvascular angina is dangerous. The WISE study followed women with non-obstructive coronary disease and impaired coronary flow reserve. Over five years, 27.6% experienced major adverse cardiovascular events. These events included myocardial infarction, stroke, hospitalization for heart failure, and cardiovascular death. This event rate exceeded what many physicians would predict for patients with mild to moderate obstructive disease. The discomfort of angina is a signal of real ischemia. The ischemia causes real myocardial injury over time. The injury leads to heart failure and death. This is not a benign condition requiring only reassurance.

Why do doctors keep telling women with chest pain that it is anxiety?

Medical education historically focused on obstructive coronary disease presenting in middle-aged men with focal plaques in large arteries. Women more often develop diffuse atherosclerosis and microvascular dysfunction. When standard angiography shows non-obstructive arteries in a woman with classic angina, the traditional framework offers no diagnosis. Physicians trained before the WISE study was published in 2006 were not taught that coronary microvascular dysfunction exists as a clinical entity. The technology to diagnose CMD, specifically invasive coronary function testing, was not part of routine catheterization protocols. Without a framework for diagnosis and without diagnostic tools, physicians attributed symptoms to anxiety. This is changing as awareness increases, but implementation remains inconsistent.